News & Updates

Show Multimedia Only

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Sotatercept, a first-in-class activin signalling inhibitor for pulmonary arterial hypertension (PAH), is approved in Hong Kong in August 2025, following regulatory approvals in Macau, the US, and the EU in February 2025.

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

Longer lactation duration tied to lower maternal CAD, stroke risks

18 Aug 2025

Extended durations of lactation appear to reduce the risk of maternal coronary artery disease (CAD) diagnosed before age 70 years, according to a study.

Longer lactation duration tied to lower maternal CAD, stroke risks

18 Aug 2025

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

Combined treatment with dapagliflozin and spironolactone results in greater reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) than dapagliflozine alone in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

16 Aug 2025 by

Women with a history of hypertensive disorders in pregnancy are at increased risk of developing brain changes that lead to Alzheimer’s disease (AD), according to a study from Singapore.

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

16 Aug 2025

Switching to DOACs may prevent stroke, bleeding in older adults

16 Aug 2025

Older patients on a vitamin K antagonist (VKA) derive benefits from switching to standard-dose (SD) direct-acting oral anticoagulant (DOAC) as shown by significant decreases in stroke or systemic embolism, fatal and intracranial bleeding, and death, reveals a study.

Switching to DOACs may prevent stroke, bleeding in older adults

16 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

Risk of device syndrome post-PFO closure higher in nickel-hypersensitive patients

15 Aug 2025 by

Findings from the INSPIRE* study demonstrate a higher risk of developing device syndrome following patent foramen ovale (PFO) closure in individuals with nickel (Ni) hypersensitivity.

Risk of device syndrome post-PFO closure higher in nickel-hypersensitive patients

15 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care

Sotatercept: A first-in-class PAH medication approved in HK

Sotatercept: A first-in-class PAH medication approved in HK

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Longer lactation duration tied to lower maternal CAD, stroke risks

Longer lactation duration tied to lower maternal CAD, stroke risks

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

Hypertension in pregnancy may be a risk factor for Alzheimer’s disease in Asians

Switching to DOACs may prevent stroke, bleeding in older adults

Switching to DOACs may prevent stroke, bleeding in older adults

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

Risk of device syndrome post-PFO closure higher in nickel-hypersensitive patients

Risk of device syndrome post-PFO closure higher in nickel-hypersensitive patients

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact